Single dose escalation studies with inhaled POL6014, a potent novel selective reversible inhibitor of human neutrophil elastase, in healthy volunteers and subjects with cystic fibrosis

POL6014 is a novel, orally inhaled neutrophil elastase (NE) inhibitor in development for cystic fibrosis (CF).

Source: Journal of Cystic Fibrosis - September 5, 2019 Category: Respiratory Medicine Authors: P. Barth, P. Bruijnzeel, A. Wach, O. Sellier Kessler, L. Hooftman, J. Zimmermann, N. Naue, B. Huber, I. Heimbeck, D. Kappeler, W. Timmer, E. Chevalier Tags: Original Article Source Type: research